Please login to the form below

Not currently logged in
Email:
Password:

cancer drug pricing

This page shows the latest cancer drug pricing news and features for those working in and with pharma, biotech and healthcare.

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing

Amid reports of price increases of several hundred per cent. Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid allegations of ... possible price-fixing among generic medicine drugs

Latest news

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    happy that NICE has made this recommendation for patients with advanced kidney cancer and their families.”. ... Nick Turkentine, chief executive of Kidney Cancer UK, said: “Today's landmark decision is hugely welcome news for kidney cancer patients

  • Italian pharma scandals prompts call for EU-wide pricing probe Italian pharma scandals prompts call for EU-wide pricing probe

    Aspen fined 5.2m for threat to halt supply of cancer drugs if price hikes not accepted. ... a possible link between drug shortages and inflated pricing.

  • NICE turns down Keytruda for lung cancer in draft guidance NICE turns down Keytruda for lung cancer in draft guidance

    Says long-term benefits for advanced non-small cell lung cancer treatment not proven. ... NICE has been taking an increasingly tough stance on cancer drug pricing, holding out for steep discounts in order to reduce the NHS' spending on medicines.

  • NICE backs five new drugs after discounts agreed NICE backs five new drugs after discounts agreed

    The UK drug-prescribing watchdog has backed the funding of five new drugs for cancer, high cholesterol and a chronic and debilitating skin disease. ... NICE had previously recommended the use of Tafinlar in melanoma in 2014 - before GlaxoSmithKline (GSK)

  • Tension expected as cancer market rises to $150bn-plus Tension expected as cancer market rises to $150bn-plus

    Last year, cancer drug sales were $107bn, an 11.5% increase on the $90bn recorded in the prior year, says the report, which has been published just as the American Society ... Debate on cancer drug pricing is expected to feature prominently alongside

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics